

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA MERCHANTS CHINA DIRECT INVESTMENTS LIMITED**

### **招商局中國基金有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 133)**

## **VOLUNTARY DISCLOSURE CAPITAL INJECTION INTO SANHOME PHARMACEUTICAL**

China Merchants China Direct Investments Limited (the “**Company**”) announces that on 3 December 2013, Shenzhen Tian Zheng Investment Co., Ltd. (“**Tian Zheng**”), a wholly-owned subsidiary of the Company, entered into an agreement (the “**Agreement**”) for capital increase in 南京聖和藥業有限公司 (Nanjing Sanhome Pharmaceutical Co., Ltd.\*, “**Sanhome Pharmaceutical**”). Pursuant to the Agreement, Tian Zheng shall make a cash injection of RMB105,000,000 into the capital of Sanhome Pharmaceutical. Upon completion of the capital injection contemplated under the Agreement, Tian Zheng will hold approximately 3.50% equity interests in the enlarged capital of Sanhome Pharmaceutical.

### **INFORMATION ABOUT SANHOME PHARMACEUTICAL**

According to the Company’s understanding, Sanhome Pharmaceutical is a pharmaceutical company as well as a national high technology enterprise. It is principally engaged in the research and development, production and sale of pharmaceutical products. The Xiaoaiping Injection, Levornidazole and Sodium Chloride Injection, Ornidazole and Sodium Chloride Injection and other products of Sanhome Pharmaceutical have a certain level of competitiveness in the market.

## **REASONS FOR AND BENEFITS OF CAPITAL INJECTION INTO SANHOME PHARMACEUTICAL**

Following the continuous development of the economy in China, the per capita consumption capacity has increased annually; it is also anticipated that the continuous increase in expenditure on life and health will lead to growth in the demand for advanced and effective medicine, thereby enhancing the development potential of the pharmaceutical industry in China in the future.

The Company believes that the major products of Sanhome Pharmaceutical will meet the demands of the market; in particular, it is expected that its Xiaoaiping Injection and its Levornidazole and Sodium Chloride Injection will have a broad market prospect.

The capital injection into Sanhome Pharmaceutical is the first investment made by the Company in the pharmaceutical industry. The Company believes that the investment in Sanhome Pharmaceutical will further optimise the Company's investment portfolio and lay a foundation for subsequent investments in the pharmaceutical industry.

For and on behalf of  
CHINA MERCHANTS CHINA DIRECT  
INVESTMENTS LIMITED  
**ZHOU Linda Lei**  
*Director*

Hong Kong, 3 December 2013

*\*For identification purposes only*

*As at the date hereof, the Executive Directors of the Company are Mr. LI Yinquan, Mr. HONG Xiaoyuan, Mr. CHU Lap Lik, Victor, Ms. ZHOU Linda Lei and Mr. TSE Yue Kit; the Non-executive Director is Mr. KE Shifeng; and the Independent Non-executive Directors are Mr. LIU Baojie, Mr. XIE Tao, Mr. ZHU Li and Mr. TSANG Wah Kwong. In addition, Ms. KAN Ka Yee, Elizabeth is the Alternate Director to Mr. CHU Lap Lik, Victor.*